Augpac: Concurrent use of amoxicillin and clavulanate potassium with probenecid may result in increased and prolonged blood levels of amoxicillin but since the excretion of clavulanic acid is unchanged by probenecid, its blood level remains unaffected.
Interaction of amoxicillin and clavulanate potassium with coumarin or indandione-derivative anticoagulants; heparin; nonsteroidal anti-inflammatory drugs (NSAIDs) especially, aspirin; other platelet aggregation inhibitors or thrombolytic agents may be clinically significant.
Amoxicillin and clavulanate potassium may decrease the efficacy of oestrogen-containing oral contraceptives.
The concurrent administration of allopurinol and amoxicillin substantially increases the incidence of rashes in patients receiving both agents as compared to patients receiving amoxicillin alone. It is not known whether this potentiation of amoxicillin rashes is due to allopurinol or the hyperuricaemia present in these patients. There are no data on amoxicillin/clavulanate combination and allopurinol administered concurrently.
Augpac Injection: Concomitant use of allopurinol during treatment with amoxicillin can increase the likelihood of allergic skin reactions.
Amoxicillin sodium and clavulanate potassium for injection should be used with care in patients on anti-coagulation therapy e.g. warfarin, as prolongation of bleeding time and prothrombin time have been reported in some patients. Amoxicillin sodium and clavulanate potassium for injection may reduce the efficacy of oral contraceptives.